Table 1 Comparison of baseline characteristics between cancer and no cancer patients in both total and matched samples
| Â | Total sample | Â | Propensity matched sample | |||||
|---|---|---|---|---|---|---|---|---|
Variable | Total (2952) | Cancer (339) | No cancer (2613) | p-Value | Total (674) | Cancer (337) | No cancer (337) | p-Value |
Age, years | 67 (56–76) | 71 (63–77) | 67 (55–75) | < 0.001 | 71 (63–77) | 71 (63–77) | 71 (61–78) | 0.79 |
Male | 1834 (62.1%) | 221 (65.2%) | 1613 (61.7%) | 0.22 | 434 (64.4%) | 220 (65.3%) | 214 (63.5%) | 0.63 |
Caucasian | 2837 (96.1%) | 337 (99%) | 2500 (95.67%) | 0.001 | 670 (99.4%) | 335 (99.4%) | 335 (99.4%) | 1.00 |
Smoking | 1941 (65.8%) | 228 (67.3%) | 1713 (65.5%) | 0.54 | 450 (66.8%) | 227 (67.3%) | 223 (66.2%) | 0.74 |
Alcohol | 1375 (46.5%) | 144 (43%) | 1231 (47%) | 0.11 | 289 (42.9%) | 144 (42.7%) | 145 (43%) | 0.94 |
BMIa, kg/m2 | 28 (24–32.6) | 28.3 (24.7–32.7) | 28 (24.6–32.6) | 0.60 | 28 (24.8–31.6) | 28.3 (24.7–32.8) | 27.8 (24.8–31) | 0.22 |
Systolic BP, mmHg | 138 (124–153) | 140 (126–156) | 138 (124–152) | 0.019 | 139 (126–155) | 140 (126–156) | 138 (125–152) | 0.22 |
Diastolic BP, mmHg | 75 (66–80) | 74 (66–80) | 75 (66–80) | 0.58 | 74 (66–80) | 74 (66–80) | 75 (68–80) | 0.41 |
Hypertension | 2684 (90.9%) | 295 (87%) | 2389 (91.4%) | 0.008 | 593 (87.9%) | 295 (87.5%) | 298 (88.4%) | 0.72 |
DM | 961 (37.6%) | 108 (31.9%) | 853 (32.6%) | 0.77 | 215 (31.9%) | 108 (32%) | 107 (31.7%) | 0.93 |
CVD | 1269 (43%) | 151 (44.5%) | 1118 (42.8%) | 0.54 | 298 (44.2%) | 151 (44.8%) | 147 (43.6%) | 0.76 |
COPD | 545 (18.5%) | 44 (12.9%) | 501 (23.7%) | 0.006 | 87 (12.9%) | 44 (13.1%) | 43 (12.7%) | 0.91 |
CLD | 88 (2.9%) | 7 (2.1%) | 81 (3.1%) | 0.29 | 13 (1.9%) | 7 (2.1%) | 6 (1.8%) | 0.78 |
RAS blocker | 1799 (61%) | 162 (47.7%) | 1637 (62.6%) | < 0.001 | 312 (46.3%) | 162 (48.1%) | 150 (44.5%) | 0.35 |
Statin | 1732 (58.7%) | 194 (57.2%) | 1538 (59%) | 0.57 | 391 (58%) | 194 (57.6%) | 197 (58.5%) | 0.82 |
ESA | 379 (12.8%) | 40 (11.8%) | 339 (13%) | 0.54 | 73 (10.8%) | 40 (11.8%) | 33 (9.8%) | 0.39 |
HB, g/L | 123 (112–135) | 121 (109–131) | 123 (112–135) | 0.02 | 122 (112–133) | 121 (110–131) | 123 (113–134) | 0.05 |
Albumin, g/L | 43 (40–45) | 43 (40–45) | 43 (40–45) | 0.30 | 43 (40–45) | 43 (40–45) | 43 (40–45) | 0.50 |
ALP, Units/L | 82 (66–104) | 85.5 (68–107) | 82 (65–103) | 0.04 | 84 (67–107) | 85.5 (68–107) | 85.5 (69–108.5) | 0.99 |
Calcium, mmol/L | 2.3 (2.2–2.4) | 2.32 (2.2–2.4) | 2.30 (2.2–2.4) | 0.17 | 2.31 (2.2–2.4) | 2.32 (2.2–2.4) | 2.30 (2.2–2.4) | 0.55 |
Phosphate, mmol/L | 1.12 (0.97–1.3) | 1.10 (0.95–1.3) | 1.12 (0.98–1.3) | 0.35 | 1.11 (0.96–1.3) | 1.10 (0.95–1.3) | 1.12 (0.97–1.3) | 0.49 |
uPCRa, g/mol | 31.5 (13–104) | 34.23 (13.2–87) | 31.2 (13–107) | 0.49 | 33.3 (13.1–90.7) | 33.7 (13.1–85) | 32.1 (13.5–94.7) | 0.64 |
Creatinine, micromol/L | 182 (135–256) | 188 (141–262) | 179 (135–254) | 0.16 | 185 (138–262) | 187 (141–261) | 183 (135–263) | 0.53 |
eGFR, mL/min/1.73m2 | 30 (19.7–42.5) | 28.3 (18.3–39.3) | 30 (19.8–43) | 0.02 | 29.3 (18.3–40.5) | 28.7 (18.5–39.4) | 29.6 (18–40.9) | 0.60 |